Transport
University of Texas Medical Branch at Galveston
University of Texas Medical Branch at Galveston was paid $150.33M by Medicaid between Apr 2018 and Dec 2024, across 429 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 37% of everything it billed.
33Billing provider infoUNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
GALVESTON, TX 77555
GALVESTON, TX 77555
33aNPI1548226988assigned 04/25/2006
33bProvider typeAmbulance
28Total paid$150.33M
24GClaims2,827,894
24DCodes billed429
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in Texas
Rank by total paid#1 of 184
Median peer was paid$197K
This provider vs. median763×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45 | $108.54 | |
| 2019 | 3,510 | $51K | |
| 2020 | 121,474 | $5.54M | |
| 2021 | 698,672 | $32.91M | |
| 2022 | 788,381 | $43.16M | |
| 2023 | 724,841 | $42.00M | |
| 2024incomplete | 490,971 | $26.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 37% | 708,485 | 605,423 | $56.02M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 47,255 | 45,780 | $11.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.3% | 14,964 | 14,007 | $7.98M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.1% | 81,509 | 77,422 | $6.18M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 67,857 | 59,507 | $6.06M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.5% | 68,458 | 65,882 | $5.28M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.4% | 36,143 | 35,324 | $3.60M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.8% | 22,895 | 21,726 | $2.74M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.4% | 451 | 436 | $2.09M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 56,065 | 54,429 | $2.07M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 66,602 | 61,980 | $2.03M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 66,595 | 61,973 | $2.03M |
417 more codes
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1.1% | 16,585 | $1.66M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.1% | 9,353 | $1.63M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.1% | 5,922 | $1.60M |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 11,810 | $1.42M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 55,223 | $1.32M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 61,260 | $1.23M |
| 81513 | <1% | 10,246 | $1.22M | |
| 76825 | <1% | 4,140 | $1.19M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,502 | $1.17M |
| 93325 | <1% | 10,901 | $1.17M | |
| 76801 | <1% | 9,452 | $1.10M | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 33,251 | $931K |
| 86850 | <1% | 25,031 | $908K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,543 | $866K |
| 99285 | Emergency room visit (most serious) | <1% | 2,026 | $839K |
| 59025 | Fetal non-stress test | <1% | 7,255 | $778K |
| 93320 | <1% | 6,157 | $756K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 762 | $738K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 119,197 | $731K |
| 86780 | <1% | 59,338 | $681K | |
| 81002 | <1% | 215,349 | $679K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 929 | $668K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,993 | $638K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 34,842 | $610K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16,175 | $606K |
| 59430 | <1% | 5,504 | $570K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 7,563 | $544K |
| 92587 | <1% | 2,669 | $464K | |
| 20610 | <1% | 2,400 | $463K | |
| 92579 | <1% | 4,572 | $438K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 789 | $420K |
| 81025 | <1% | 44,512 | $407K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,434 | $375K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,942 | $372K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 35,852 | $358K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 6,523 | $335K |
| 92567 | <1% | 9,765 | $331K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 46,284 | $319K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,665 | $315K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,615 | $301K |
| 87653 | <1% | 9,549 | $291K | |
| 76770 | <1% | 2,187 | $277K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,455 | $274K |
| 88142 | <1% | 15,645 | $272K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,408 | $262K |
| 87631 | <1% | 1,894 | $252K | |
| 90715 | <1% | 9,083 | $250K | |
| 17110 | <1% | 2,001 | $248K | |
| 86762 | <1% | 20,221 | $232K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 3,309 | $230K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 8,864 | $227K |
| 80053 | Comprehensive metabolic panel | <1% | 20,313 | $223K |
| 76827 | <1% | 2,869 | $223K | |
| 86769 | <1% | 6,271 | $218K | |
| 92557 | <1% | 2,347 | $214K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,631 | $213K |
| 97162 | <1% | 3,557 | $213K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 6,608 | $186K |
| 86787 | <1% | 17,253 | $178K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,873 | $173K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 11,054 | $172K |
| 87634 | <1% | 2,546 | $168K | |
| 87340 | <1% | 21,417 | $153K | |
| 84702 | <1% | 11,631 | $150K | |
| 87481 | <1% | 10,372 | $149K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 20,985 | $145K |
| 92523 | <1% | 738 | $144K | |
| 54162 | <1% | 57 | $141K | |
| 95782 | <1% | 196 | $136K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,339 | $136K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,167 | $133K |
| 80050 | General health panel | <1% | 1,904 | $131K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,647 | $131K |
| 95812 | <1% | 676 | $124K | |
| 92650 | <1% | 1,062 | $120K | |
| 92550 | <1% | 1,431 | $113K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,130 | $113K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 713 | $111K |
| 92582 | <1% | 1,148 | $109K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,788 | $109K |
| 82105 | <1% | 7,245 | $106K | |
| 0001A | <1% | 4,728 | $104K | |
| 86803 | <1% | 11,701 | $104K | |
| 0002A | <1% | 4,443 | $99K | |
| 82947 | <1% | 29,756 | $96K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,777 | $94K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,460 | $91K |
| 76830 | Ultrasound, transvaginal | <1% | 899 | $90K |
| 82677 | <1% | 4,138 | $89K | |
| 54161 | <1% | 98 | $88K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,545 | $83K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,628 | $82K |
| 97166 | <1% | 1,366 | $80K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 930 | $80K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,566 | $80K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,403 | $71K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,730 | $66K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,529 | $66K |
| 86900 | <1% | 25,392 | $65K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 270 | $64K |
| 85055 | <1% | 3,173 | $64K | |
| 81001 | <1% | 21,451 | $63K | |
| 86901 | <1% | 25,398 | $63K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,335 | $60K |
| 92555 | <1% | 1,441 | $59K | |
| 86336 | <1% | 4,141 | $57K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,368 | $57K |
| 92060 | <1% | 1,579 | $54K | |
| 80061 | Lipid panel | <1% | 7,393 | $51K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,600 | $50K |
| 29065 | <1% | 131 | $50K | |
| S8101 | Holding chamber or spacer for use with an inhaler or nebulizer; with mask | <1% | 1,062 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,257 | $47K |
| 73630 | <1% | 1,680 | $47K | |
| 51798 | <1% | 644 | $44K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 616 | $44K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 495 | $43K |
| 97163 | <1% | 771 | $41K | |
| 97161 | <1% | 669 | $39K | |
| 92652 | <1% | 168 | $38K | |
| 83880 | <1% | 2,764 | $37K | |
| 94760 | <1% | 8,481 | $35K | |
| 90674 | <1% | 5,007 | $34K | |
| 87088 | <1% | 5,261 | $34K | |
| 73110 | <1% | 645 | $33K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 402 | $33K |
| 73610 | <1% | 947 | $33K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 254 | $31K |
| 82728 | <1% | 2,884 | $29K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,064 | $29K |
| 96900 | <1% | 668 | $29K | |
| 92552 | <1% | 352 | $26K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,277 | $26K |
| 82951 | <1% | 2,355 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 338 | $25K |
| 76813 | <1% | 233 | $25K | |
| 84439 | <1% | 4,590 | $24K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 26 | $24K |
| 73130 | <1% | 647 | $23K | |
| 84484 | <1% | 4,460 | $22K | |
| 73562 | <1% | 823 | $22K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 181 | $22K |
| 97164 | <1% | 471 | $20K | |
| 90651 | <1% | 173 | $19K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 112 | $19K |
| 88720 | <1% | 4,295 | $19K | |
| 69210 | <1% | 366 | $19K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,559 | $19K |
| J3490 | Unclassified drugs | <1% | 733 | $18K |
| 99000 | <1% | 1,454 | $16K | |
| 80076 | <1% | 3,712 | $16K | |
| 87536 | <1% | 292 | $16K | |
| 87186 | <1% | 3,917 | $16K | |
| 83690 | <1% | 3,936 | $15K | |
| 87563 | <1% | 476 | $14K | |
| 98960 | <1% | 543 | $14K | |
| 76820 | <1% | 271 | $14K | |
| 83735 | <1% | 6,111 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 324 | $14K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 228 | $13K |
| 86833 | <1% | 402 | $13K | |
| 90677 | <1% | 124 | $13K | |
| 87081 | <1% | 1,466 | $13K | |
| 87077 | <1% | 3,301 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $12K |
| 76885 | <1% | 139 | $12K | |
| 86832 | <1% | 403 | $12K | |
| 96160 | <1% | 537 | $12K | |
| 72081 | <1% | 251 | $12K | |
| 29075 | <1% | 35 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 146 | $12K |
| 83970 | <1% | 889 | $11K | |
| 92526 | <1% | 219 | $11K | |
| 72170 | <1% | 283 | $10K | |
| 86592 | <1% | 2,600 | $10K | |
| 17250 | <1% | 101 | $10K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 112 | $10K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 524 | $10K |
| 72100 | <1% | 387 | $10K | |
| 86003 | <1% | 161 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,380 | $9K |
| 90678 | <1% | 100 | $9K | |
| 92134 | <1% | 582 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 209 | $9K |
| 73090 | <1% | 210 | $9K | |
| 90686 | <1% | 1,319 | $9K | |
| 81003 | <1% | 3,781 | $9K | |
| 73030 | <1% | 482 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,728 | $8K |
| 0004A | <1% | 569 | $8K | |
| 74018 | <1% | 414 | $8K | |
| 11721 | <1% | 250 | $8K | |
| 82607 | <1% | 1,300 | $8K | |
| 84436 | <1% | 1,105 | $8K | |
| 99152 | <1% | 160 | $7K | |
| 90661 | <1% | 1,258 | $7K | |
| 84481 | <1% | 1,170 | $7K | |
| 84703 | <1% | 1,102 | $7K | |
| 0071A | <1% | 211 | $7K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 385 | $7K |
| 85610 | <1% | 3,647 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 45 | $7K |
| 82570 | <1% | 3,662 | $7K | |
| 85027 | <1% | 2,095 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,362 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,412 | $6K |
| 92553 | <1% | 71 | $6K | |
| 92556 | <1% | 182 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 356 | $6K |
| 83550 | <1% | 1,418 | $6K | |
| 93786 | <1% | 90 | $6K | |
| 86696 | <1% | 372 | $6K | |
| 0011A | <1% | 319 | $6K | |
| 0012A | <1% | 280 | $5K | |
| 92504 | <1% | 177 | $5K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 88 | $5K |
| 83516 | <1% | 436 | $5K | |
| 0054A | <1% | 243 | $5K | |
| 85046 | <1% | 823 | $5K | |
| 91320 | <1% | 216 | $5K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 51 | $5K |
| 0072A | <1% | 138 | $5K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 651 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,803 | $5K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,992 | $4K |
| 82248 | <1% | 1,329 | $4K | |
| 86870 | <1% | 16 | $4K | |
| 85730 | <1% | 1,453 | $4K | |
| 73502 | <1% | 253 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,265 | $4K |
| 73070 | <1% | 90 | $4K | |
| 11900 | <1% | 30 | $4K | |
| 84100 | <1% | 3,352 | $4K | |
| 88304 | <1% | 555 | $4K | |
| 86376 | <1% | 281 | $4K | |
| 83605 | <1% | 795 | $4K | |
| 86695 | <1% | 372 | $4K | |
| 83540 | <1% | 1,332 | $4K | |
| 97165 | <1% | 75 | $4K | |
| 82803 | <1% | 358 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,983 | $4K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 27 | $4K |
| 72082 | <1% | 37 | $4K | |
| 84156 | <1% | 2,402 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 73 | $4K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 638 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 27 | $4K |
| S0620 | Routine ophthalmological examination including refraction; new patient | <1% | 212 | $4K |
| 92586 | <1% | 41 | $4K | |
| 92610 | <1% | 58 | $3K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 57 | $3K |
| 86800 | <1% | 224 | $3K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 39 | $3K |
| 86140 | <1% | 1,209 | $3K | |
| 82784 | <1% | 363 | $3K | |
| 87147 | <1% | 1,114 | $3K | |
| 87070 | <1% | 800 | $3K | |
| 76775 | <1% | 44 | $3K | |
| 87529 | <1% | 108 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,175 | $3K |
| 86481 | <1% | 58 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 145 | $3K |
| 80197 | <1% | 988 | $3K | |
| 87040 | <1% | 551 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 239 | $3K |
| 83615 | <1% | 653 | $3K | |
| 93971 | <1% | 53 | $3K | |
| 84163 | <1% | 202 | $2K | |
| 87205 | <1% | 971 | $2K | |
| 95886 | <1% | 24 | $2K | |
| 84550 | <1% | 942 | $2K | |
| 31231 | <1% | 13 | $2K | |
| 92585 | <1% | 14 | $2K | |
| 84425 | <1% | 121 | $2K | |
| 0124A | <1% | 186 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 786 | $2K |
| 82746 | <1% | 312 | $2K | |
| 73590 | <1% | 81 | $2K | |
| 69209 | <1% | 36 | $2K | |
| 82043 | <1% | 1,187 | $2K | |
| 80321 | <1% | 186 | $2K | |
| 90480 | <1% | 240 | $2K | |
| 87807 | <1% | 153 | $2K | |
| 0064A | <1% | 185 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 73 | $2K |
| 70496 | <1% | 24 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 343 | $2K |
| 0003A | <1% | 187 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,051 | $2K |
| J0485 | Injection, belatacept, 1 mg | <1% | 26 | $2K |
| S9152 | Speech therapy, re-evaluation | <1% | 13 | $2K |
| 31575 | <1% | 13 | $2K | |
| 97802 | <1% | 83 | $2K | |
| 88342 | <1% | 13 | $2K | |
| 85660 | <1% | 392 | $2K | |
| 82565 | <1% | 502 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 72 | $1K |
| 86706 | <1% | 257 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 88 | $1K |
| 76641 | <1% | 28 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,027 | $1K |
| 82550 | <1% | 442 | $1K | |
| 87497 | <1% | 227 | $1K | |
| 97168 | <1% | 29 | $1K | |
| 86593 | <1% | 759 | $1K | |
| 0031A | <1% | 65 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 218 | $1K |
| 85652 | <1% | 771 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 670 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 227 | $1K |
| 92015 | Determination of refractive state | <1% | 54 | $1K |
| 96127 | <1% | 343 | $1K | |
| 82465 | <1% | 406 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 512 | $918.99 |
| S8100 | Holding chamber or spacer for use with an inhaler or nebulizer; without mask | <1% | 155 | $918.23 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 92 | $908.23 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 611 | $901.17 |
| 70498 | <1% | 12 | $880.25 | |
| 96381 | <1% | 19 | $870.10 | |
| 84305 | <1% | 39 | $855.16 | |
| 93017 | <1% | 14 | $848.78 | |
| 85379 | <1% | 179 | $821.72 | |
| 74019 | <1% | 27 | $818.74 | |
| 11102 | <1% | 12 | $775.98 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 28 | $767.38 |
| 97803 | <1% | 30 | $739.60 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 42 | $725.66 |
| 84155 | <1% | 1,341 | $714.32 | |
| 84153 | <1% | 107 | $704.73 | |
| 72131 | <1% | 14 | $696.99 | |
| 82977 | <1% | 91 | $680.13 | |
| 87102 | <1% | 101 | $655.07 | |
| 84146 | <1% | 165 | $643.73 | |
| 90732 | <1% | 25 | $641.53 | |
| 0134A | <1% | 60 | $624.82 | |
| 71250 | <1% | 14 | $615.79 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 604 | $601.50 |
| 77072 | <1% | 27 | $586.17 | |
| L8613 | Ossicula implant | <1% | 297 | $562.42 |
| 87420 | <1% | 81 | $548.82 | |
| 86580 | <1% | 12 | $523.41 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 31 | $522.96 |
| 83655 | <1% | 37 | $504.55 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 92 | $489.76 |
| 92133 | <1% | 30 | $481.64 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 124 | $475.35 |
| 84460 | <1% | 144 | $475.27 | |
| 84450 | <1% | 145 | $464.18 | |
| 77080 | <1% | 75 | $458.29 | |
| 82150 | <1% | 132 | $435.10 | |
| 73521 | <1% | 12 | $424.92 | |
| 74022 | <1% | 14 | $421.00 | |
| 82785 | <1% | 32 | $411.06 | |
| 72040 | <1% | 12 | $407.57 | |
| 87799 | <1% | 136 | $403.47 | |
| 82340 | <1% | 70 | $402.24 | |
| 85018 | <1% | 145 | $350.10 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 217 | $349.10 |
| 86038 | <1% | 59 | $348.24 | |
| 80306 | <1% | 25 | $345.60 | |
| 86255 | <1% | 57 | $326.68 | |
| C1769 | Guide wire | <1% | 467 | $318.00 |
| 95012 | <1% | 16 | $305.30 | |
| 85247 | <1% | 12 | $302.88 | |
| 85246 | <1% | 12 | $302.88 | |
| 85245 | <1% | 12 | $302.88 | |
| 85240 | <1% | 15 | $295.50 | |
| 86160 | <1% | 23 | $277.20 | |
| 86361 | <1% | 14 | $265.50 | |
| 17000 | <1% | 12 | $248.97 | |
| 73552 | <1% | 14 | $248.64 | |
| 87220 | <1% | 48 | $234.77 | |
| 93296 | <1% | 18 | $223.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 208 | $212.57 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 385 | $211.47 |
| 87641 | <1% | 14 | $183.96 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 82 | $178.27 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 400 | $173.56 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 31 | $170.51 |
| 87640 | <1% | 14 | $145.34 | |
| 0013A | <1% | 53 | $138.88 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,587 | $138.50 |
| C9399 | Unclassified drugs or biologicals | <1% | 207 | $125.33 |
| 90633 | <1% | 21 | $114.77 | |
| 83001 | <1% | 17 | $104.27 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 30 | $85.02 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 102 | $79.82 |
| 84300 | <1% | 17 | $68.10 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 34 | $66.01 |
| 84133 | <1% | 17 | $60.30 | |
| 81015 | <1% | 14 | $50.12 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 49 | $43.12 |
| 86704 | <1% | 13 | $40.48 | |
| 96376 | <1% | 42 | $36.16 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,182 | $27.77 |
| 90694 | <1% | 388 | $27.42 | |
| 82962 | <1% | 2,470 | $6.25 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 26 | $5.88 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,488 | $5.40 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 88 | $4.31 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 927 | $2.43 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,929 | $0.13 |
| G0008 | Administration of influenza virus vaccine | 0% | 1,012 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 71 | $0.00 |
| 36416 | 0% | 557 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 43 | $0.00 |
| 95806 | 0% | 13 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 12 | $0.00 |
| 0753T | 0% | 664 | $0.00 | |
| 0752T | 0% | 88 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 198 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 97 | $0.00 |
| 90653 | 0% | 77 | $0.00 | |
| C1780 | Lens, intraocular (new technology) | 0% | 13 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 13 | $0.00 |
| 90461 | 0% | 17 | $0.00 | |
| 90380 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREISER, JOCHEN (PRESIDENT)